Prevention & lipidsCohort study
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
- Prospective cohort study
Authors' conclusion
Excess apoB (ie, the value of apoB above that contributed by LDL-C levels alone) is associated dose-dependently with an increased risk of MI and ASCVD in women and men.
Study context
- Population
- Women and men not taking statins, Copenhagen General Population Study53,484 women and 41,624 men
- Exposure
- Categories of excess apolipoprotein B (apoB)
- Outcome
- MI, ASCVD and all-cause mortality
- Follow-up
- Median 9.6 years
Main finding
As reported in the abstract
ASCVD
Each group vs <11 mg/dLHazard ratio (95% CI)
11 to 25 mg/dLwomen
1.08(0.97–1.21)
26 to 45 mg/dLwomen
1.30(1.14–1.48)
46 to 100 mg/dLwomen
1.34(1.14–1.58)
>100 mg/dLwomen
1.75(1.08–2.83)
11 to 25 mg/dLmen
1.14(1.02–1.26)
26 to 45 mg/dLmen
1.41(1.26–1.57)
46 to 100 mg/dLmen
1.41(1.25–1.60)
>100 mg/dLmen
1.52(1.13–2.05)
Observational data: associations, not effects.
Further findings
Across low-density lipoprotein cholesterol (LDL-C) spectrum
- Results robust across the entire LDL-C spectrum
Original publication
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. J Am Coll Cardiol. Published 11 June 2024. doi:10.1016/j.jacc.2024.03.423
Summarised from the published abstract; every number is checked against it